Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 1, 2017

Almac Expands in Ireland

The company announced an investment in a new facility in Dundalk, County Louth, Ireland.

On Jan. 26, 2017 Almac Group announced that as part of its ongoing global expansion, the company has secured a new facility in Dundalk, County Louth, Ireland. The new facility will be located at IDA Business Park. The new facility will increase the group’s European footprint by 32,000 ft2. The Dundalk facility will be utilized by Almac Pharma Services and Almac Clinical Services.

In November 2016, the company announced expansion projects in Pennsylvania and Northern Ireland. Almac said it would invest £20-million (approximately $25.28-million) at its site in Souderton, PA to expand its existing 240,000-ft2 facility in addition to leasing a 26,000-ft2 office space in nearby Lansdale, PA. In Northern Ireland, Almac said it would invest around £5 million (approximately $6.32-million) in Craigavon to build an additional laboratory and office facility.

“Almac’s decision to expand into Dundalk provides the company with certainty of access to the European Union in the long term-this certainty of access is an increasingly important selling point for Ireland as we look to win business for Ireland,” Martin Shanahan, CEO, IDA Ireland said in a statement.

Source: Almac


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.